Document Classification

Section Type: RESULTS

Text: In patients with previous stroke (n = 486 in the pioglitazone group and n = 498 in the placebo group), there was a trend of benefit with pioglitazone for the primary end point of all-cause death, nonfatal myocardial infarction, acute coronary syndrome, and cardiac intervention (including coronary artery bypass graft or percutaneous coronary intervention), stroke, major leg amputation, or bypass surgery or leg revascularization (hazard ratio [HR] = 0. 78, event rate = 20. 2 % pioglitazone vs 25. 3 % placebo ; 95 % CI = 0. 60-1. 02 ; P = 0. 0670) and for the main secondary end point of all-cause death, nonfatal myocardial infarction, or nonfatal stroke (HR = 0. 78, event rate = 15. 6 % pioglitazone vs 19. 7 % placebo ; 95 % CI = 0. 58-1. 06 ; P = 0. 1095).